Skip to content
10-Q

Quarterly Report

Anika Therapeutics, Inc. ANIK

0001171843-25-007032

← back to feed
Filed
Nov 5, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 29, 2025 14.42M sh
Shares Diluted Q3 2025 · Sep 30, 2025 14.42M sh
Shares Diluted Q3 2025 · Sep 30, 2025 14.36M sh
Shares Diluted Q3 2025 · Sep 30, 2024 14.77M sh
Shares Diluted Q3 2025 · Sep 30, 2024 14.77M sh
Stock Repurchased Q3 2025 · Sep 30, 2025 $3.97M
Stock Repurchased Q3 2025 · Sep 30, 2024 $5.34M
Capex Q3 2025 · Sep 30, 2025 $6.18M
Capex Q3 2025 · Sep 30, 2024 $6.43M
Operating Cash Flow Q3 2025 · Sep 30, 2025 $6.55M
Operating Cash Flow Q3 2025 · Sep 30, 2024 $3.82M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $57.99M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $55.63M
Stockholders Equity Q3 2025 · Sep 30, 2025 $146.81M
Stockholders Equity Q3 2025 · Jun 30, 2025 $147.67M
Stockholders Equity Q3 2025 · Mar 31, 2025 $148.4M
Stockholders Equity Q3 2025 · Dec 31, 2024 $153.99M
Stockholders Equity Q3 2025 · Sep 30, 2024 $179.86M
Stockholders Equity Q3 2025 · Jun 30, 2024 $210.34M
Stockholders Equity Q3 2025 · Mar 31, 2024 $208.54M
Stockholders Equity Q3 2025 · Dec 31, 2023 $212.27M
Current Liabilities Q3 2025 · Sep 30, 2025 $19.09M
Current Liabilities Q3 2025 · Dec 31, 2024 $23.31M
Current Assets Q3 2025 · Sep 30, 2025 $101.59M
Current Assets Q3 2025 · Dec 31, 2024 $113.65M
Total Assets Q3 2025 · Sep 30, 2025 $189.44M
Total Assets Q3 2025 · Dec 31, 2024 $202.74M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.16
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.78
Eps Diluted Q3 2025 · Sep 30, 2024 −$2.03
Eps Diluted Q3 2025 · Sep 30, 2024 −$2.34
Eps Basic Q3 2025 · Sep 30, 2025 −$0.16
Eps Basic Q3 2025 · Sep 30, 2025 −$0.78
Eps Basic Q3 2025 · Sep 30, 2024 −$2.03
Eps Basic Q3 2025 · Sep 30, 2024 −$2.34
Sga Expense Q3 2025 · Sep 30, 2025 $11.87M
Sga Expense Q3 2025 · Sep 30, 2025 $37.01M
Sga Expense restated Q3 2025 · Sep 30, 2024 $13.54M
Sga Expense restated Q3 2025 · Sep 30, 2024 $44.23M
Rd Expense Q3 2025 · Sep 30, 2025 $6.95M
Rd Expense Q3 2025 · Sep 30, 2025 $19.32M
Rd Expense restated Q3 2025 · Sep 30, 2024 $5.95M
Rd Expense restated Q3 2025 · Sep 30, 2024 $19.04M
Net Income Q3 2025 · Sep 30, 2025 −$2.33M
Net Income Q3 2025 · Sep 30, 2025 −$11.17M
Net Income Q3 2025 · Jun 30, 2025 −$3.97M
Net Income Q3 2025 · Mar 31, 2025 −$4.87M
Net Income Q3 2025 · Sep 30, 2024 −$29.92M
Net Income Q3 2025 · Sep 30, 2024 −$34.52M
Net Income Q3 2025 · Jun 30, 2024 −$88K
Net Income Q3 2025 · Mar 31, 2024 −$4.51M
Operating Income Q3 2025 · Sep 30, 2025 −$3.23M
Operating Income Q3 2025 · Sep 30, 2025 −$11.7M
Operating Income restated Q3 2025 · Sep 30, 2024 −$81K
Operating Income restated Q3 2025 · Sep 30, 2024 −$4.4M
Gross Profit Q3 2025 · Sep 30, 2025 $15.58M
Gross Profit Q3 2025 · Sep 30, 2025 $44.63M
Gross Profit restated Q3 2025 · Sep 30, 2024 $19.41M
Gross Profit restated Q3 2025 · Sep 30, 2024 $58.87M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $12.23M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $37.58M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $10.15M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $30.43M
Revenue Q3 2025 · Sep 30, 2025 $27.82M
Revenue Q3 2025 · Sep 30, 2025 $82.2M
Revenue restated Q3 2025 · Sep 30, 2024 $29.56M
Revenue restated Q3 2025 · Sep 30, 2024 $89.31M